Big Pharma Split Stock Net Asset
| PRM Stock | CAD 12.94 0.06 0.46% |
Big Pharma Split fundamentals help investors to digest information that contributes to Big Pharma's financial success or failures. It also enables traders to predict the movement of Big Stock. The fundamental analysis module provides a way to measure Big Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Big Pharma stock.
Big | Net Asset |
Big Pharma Split Company Net Asset Analysis
Big Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Big Pharma Net Asset | 26.53 M |
Most of Big Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Big Pharma Split is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Big Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Big Pharma is extremely important. It helps to project a fair market value of Big Stock properly, considering its historical fundamentals such as Net Asset. Since Big Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Big Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Big Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Big Total Assets
Total Assets |
|
Based on the recorded statements, Big Pharma Split has a Net Asset of 26.53 M. This is much higher than that of the Capital Markets sector and significantly higher than that of the Financials industry. The net asset for all Canada stocks is notably lower than that of the firm.
Big Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Big Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Big Pharma could also be used in its relative valuation, which is a method of valuing Big Pharma by comparing valuation metrics of similar companies.Big Pharma is currently under evaluation in net asset category among its peers.
Big Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Big Pharma from analyzing Big Pharma's financial statements. These drivers represent accounts that assess Big Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Big Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 13.3M | 18.9M | 22.0M | 16.7M | 15.1M | 13.9M | |
| Enterprise Value | 22.5M | 32.3M | 31.0M | 26.8M | 24.1M | 22.6M |
Big Fundamentals
| Return On Equity | -0.0363 | ||||
| Return On Asset | -0.0069 | ||||
| Profit Margin | (2.01) % | ||||
| Operating Margin | 0.51 % | ||||
| Current Valuation | (9.41 M) | ||||
| Shares Outstanding | 1.13 M | ||||
| Number Of Shares Shorted | 100 | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 45.60 X | ||||
| Revenue | 311.76 K | ||||
| Gross Profit | 320.82 K | ||||
| EBITDA | (139.68 K) | ||||
| Net Income | (645.35 K) | ||||
| Total Debt | 10.3 M | ||||
| Book Value Per Share | 13.99 X | ||||
| Cash Flow From Operations | 11.86 M | ||||
| Short Ratio | 1.19 X | ||||
| Earnings Per Share | 0.99 X | ||||
| Target Price | 2.0 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 14.63 M | ||||
| Total Asset | 26.53 M | ||||
| Annual Yield | 0.09 % | ||||
| Net Asset | 26.53 M | ||||
| Last Dividend Paid | 1.24 |
About Big Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Big Pharma Split's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Big Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Big Pharma Split based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Big Stock
| 0.55 | ELF | E L Financial Earnings Call This Week | PairCorr |
| 0.47 | ELF-PH | E L Financial Earnings Call This Week | PairCorr |
| 0.46 | BRK | Berkshire Hathaway CDR | PairCorr |
| 0.37 | FFH | Fairfax Financial | PairCorr |
| 0.31 | FFH-PM | Fairfax Financial | PairCorr |
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.